2022 World Conference on Lung Cancer (ePosters)-EP16.04-006. A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis

EP16.04-006. A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis

Pdf Summary

This study aimed to understand the role of cancer-associated fibroblasts (CAFs) in lung cancer progression and metastasis. The researchers developed an orthotopic xenograft (OX) mouse model to study CAFs and lymphangiogenesis in lung cancer. They established lung CAFs by co-culturing non-small cell lung cancer cell lines with a normal human lung fibroblast cell line. The activated CAFs were then injected into the left lung of nude mice to establish the OX model.<br /><br />The results showed that the lung tumors derived from CAFs had more prominent peritumoral lymphangiogenesis and increased mediastinal lymph node metastases compared to tumors without CAFs. The researchers also administered an inhibitor of CAFs, Venetoclax, through oral gavage and found that it significantly reduced CAFs and tumor-associated lymphangiogenesis in the OX model.<br /><br />Overall, this study demonstrated that lung CAFs activated by lung cancer cells can enhance tumor-associated lymphangiogenesis and mediastinal lymph node metastases. It also suggests that Venetoclax can be used to target lung CAFs and reduce lymphangiogenesis in non-small cell lung cancer.<br /><br />This orthotopic xenograft mouse model provides a necessary environment for studying the biological functions of lung CAFs and potential therapeutic interventions. It can be used to investigate the mechanisms of CAFs in lung cancer progression and test novel treatments targeting CAFs and lymphangiogenesis.

Asset Subtitle

Caoyang Chen

Meta Tag

Speaker Caoyang Chen

Topic Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

Keywords

cancer-associated fibroblasts

lung cancer progression

metastasis

orthotopic xenograft mouse model

lymphangiogenesis

non-small cell lung cancer

activated CAFs

mediastinal lymph node metastases

Venetoclax

therapeutic interventions